Novel Bioresorbable Drug-Eluting Mesh Scaffold for Therapy of Muscle Injury
ACS Biomaterials Science & Engineering · 08.04.2024 · 10 (4) · 2595-2606
DOI: 10.1021/acsbiomaterials.3c01669 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Biomaterials Science & Engineering, online erschienen am 14.03.2024. Verfasst von Ying-Chao Chou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Bone and Joint Research Center, Department of Orthopedics, Chang Gung Memorial Hospital at Linkou, Taoyuan 33305, Taiwan. Hauptthemen laut MEDLINE: Absorbable Implants, Surgical Mesh. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Science Council, Chang Gung Memorial Hospital.
Abstract (Originalsprache)
A novel bioresorbable drug-eluting polycaprolactone (PCL) mesh scaffold was developed, utilizing a solvent-cast additive manufacturing technique, to promote therapy of muscle injury. The degradation rate and mechanical properties strength of the PCL mesh were characterized after immersion in a buffer solution for different times. The in vitro release characteristics of vancomycin, ceftazidime, and lidocaine from the prepared mesh were evaluated using a high-performance liquid chromatography (HPLC) assay. In addition, the in vivo efficacy of PCL meshes for the repair of muscle injury was investigated on a rat model with histological examinations. It was found that the additively manufactured PCL meshes degraded by 13% after submission in buffered solution for four months. All PCL meshes with different pore sizes exhibited greater strength than rat muscle and survived through 10,000 cyclic loadings. Furthermore, the meshes could offer a sustained release of antibiotics and analgesics for more than 3 days in vitro. The results of this study suggest that drug-loaded PCL mesh exhibits superior ability to pure PCL mesh in terms of effectively promoting muscle repair in rat models. The histological assay also showed adequate biocompatibility of the resorbable meshes. The additively manufactured biodegradable drug-eluting meshes may be adopted in the future in humans for the therapy of muscle injuries.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bone and Joint Research Center, Department of Orthopedics, Chang Gung Memorial Hospital at Linkou, Taoyuan 33305, Taiwan.
- Department of Mechanical Engineering, Chang Gung University, Taoyuan 33302, Taiwan.
- Department of Medical Biotechnology and Laboratory Science, Chang Gung University, Taoyuan 33302, Taiwan.
ORCID-Profile: Shih-Jung Liu
Förderung
- National Science Council
- Chang Gung Memorial Hospital
Zitieren
APA
Chou, Y. C., Hsu, Y. H., Lee, D., Yang, J. W., Yu, Y. H., Chan, E. C., & Liu, S. J. (2024). Novel Bioresorbable Drug-Eluting Mesh Scaffold for Therapy of Muscle Injury. ACS Biomaterials Science & Engineering, 10(4), 2595-2606. https://doi.org/10.1021/acsbiomaterials.3c01669
Vancouver
Chou YC, Hsu YH, Lee D, Yang JW, Yu YH, Chan EC, et al. Novel Bioresorbable Drug-Eluting Mesh Scaffold for Therapy of Muscle Injury. ACS Biomaterials Science & Engineering. 2024;10(4):2595-2606. doi:10.1021/acsbiomaterials.3c01669
BibTeX
@article{Chou2024,
author = {Chou, Ying-Chao and Hsu, Yung-Heng and Lee, Demei and Yang, Jheng-Wei and Yu, Yi-Hsun and Chan, Err-Cheng and Liu, Shih-Jung},
title = {Novel Bioresorbable Drug-Eluting Mesh Scaffold for Therapy of Muscle Injury},
journal = {ACS Biomaterials Science & Engineering},
year = {2024},
volume = {10},
number = {4},
pages = {2595--2606},
doi = {10.1021/acsbiomaterials.3c01669}
}
EUVIMED